Table 2.

Association results between the five polymorphisms and the risk of developing DTC

Genotypes	Genotyped participants		Crude OR a (95% CI)	p-value	Adjusted OR b (95% CI)	Adjusted OR per allele (95% CI)	p-value
	Cases n (%)	Controls n (%)
rs1801516 (ATM)	n = 197	n = 206
G/G	153	162	Ref		Ref
G/A	44	42	1.2 (0.7–1.9)	0.6	1.2 (0.7–2.0)	1.1 (0.7–1.7)	0.8
A/A	0	2	-	0.9	-
rs944289 (near NKX2-1)	n = 202	n = 209
C/C	47	70	Ref		Ref
C/T	85	98	1.3 (0.8–2.0)	0.4	1.2 (0.7–1.9)	1.6 (1.1–2.1)	0.02
T/T	70	41	2.6 (1.5–4.5)	<0.001	2.5 (1.4–4.4)
rs965513 (near FOXE1)	n = 203	n = 212
G/G	83	118	Ref		Ref
G/A	91	81	2.0 (1.0–4.1)	0.06	1.7 (1.1–2.6)	1.7 (1.2–2.3)	0.02
A/A	29	13	3.3 (1.16–6.9)	0.001	2.9 (1.3–6.1)
rs1867277 (5′UTR of FOXE1)	n = 203	n = 212
G/G	56	88	Ref		Ref
G/A	104	91	1.1 (0.7–1.9)	0.6	1.8 (1.2–2.9)	1.5 (1.1–1.9)	0.01
A/A	43	33	2.1 (1.2–3.8)	<0.01	1.9 (1.1–3.5)
rs71369530 (length polymorphism in FOXE1)	n = 203	n = 212
S/Sc	72	112	Ref		Ref
S/Lc	101	84	1.5 (0.8–3.0)	0.2	2.0 (1.3–3.1)	1.8 (1.3–2.5)	0.0003
L/Lc	30	16	2.9 (1.5–5.7)	<0.005	2.9 (1.4–5.9)

^aStratified by age and sex.

^bStratified by age and sex and adjusted on BSA, ethnicity, tobacco, size and for women, number of pregnancies.

^cS for alleles with 14 or fewer alanine residues and L for alleles with 16 or more alanine residues.